CHOROIDAL VASCULAR HYPERPERMEABILITY AS A PREDICTOR OF TREATMENT RESPONSE FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
- 1 August 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Retina
- Vol. 38 (8) , 1509-1517
Abstract
Purpose: To investigate the influence of choroidal vascular hyperpermeability (CVH) and choroidal thickness on treatment outcomes in eyes with polypoidal choroidal vasculopathy (PCV) undergoing anti–vascular endothelial growth factor monotherapy or combination therapy of photodynamic therapy and anti–vascular endothelial growth factor injections. Methods: The authors performed a prospective, observational cohort study involving 72 eyes of 72 patients with polypoidal choroidal vasculopathy (mean age 68.6 years, 51% men) treated with either monotherapy (n = 41) or combination therapy (n = 31). Each eye was imaged with color fundus photography, fluorescent angiography, indocyanine green angiography, and spectral domain optical coherence tomography. Indocyanine green angiography images were used to evaluate CVH, and spectral domain optical coherence tomography was used to measure central choroidal thickness. Changes in visual acuity over 12 months, and number of anti–vascular endothelial growth factor injections were investigated. Results: Choroidal vascular hyperpermeability was present in 31 eyes (43.1%). Visual acuity change over 12 months was numerically better in the CVH group compared with the CVH (−) group (−0.099 and −0.366 logarithm of the minimal angle of resolution unit in the CVH (−) and CVH (+) groups, respectively, multivariate P = 0.063) and significantly better in a matched pair analysis (P = 0.033). Furthermore, in the combination therapy group, the number of injection was significantly lower in the CVH (+) group compared with the CVH (−) group (4.68 vs. 2.58 injections/year in the CVH (−) and CVH (+) groups; P = 0.0044). There was no significant relationship between treatment response and choroidal thickening. Conclusion: The presence of CVH is associated with better visual outcome in eyes with polypoidal choroidal vasculopathy and lower injection number in combination therapy. Thus, CVH, but not choroidal thickness, should be further evaluated as a potential biomarker for selecting patients for combination therapy.Keywords
This publication has 41 references indexed in Scilit:
- Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumabBMC Ophthalmology, 2013
- Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2013
- Asian age‐related macular degeneration phenotyping study: rationale, design and protocol of a prospective cohort studyClinical & Experimental Ophthalmology, 2012
- Choroidal Thickness in Polypoidal Choroidal Vasculopathy and Exudative Age-related Macular DegenerationOphthalmology, 2011
- Subfoveal Retinal and Choroidal Thickness After Verteporfin Photodynamic Therapy for Polypoidal Choroidal VasculopathyAmerican Journal of Ophthalmology, 2011
- One-Year Outcomes of Photodynamic Therapy in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Japanese PatientsOphthalmology, 2008
- Clinical Characteristics of Exudative Age-related Macular Degeneration in Japanese PatientsAmerican Journal of Ophthalmology, 2007
- Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathyBritish Journal of Ophthalmology, 2007
- Polypoidal Choroidal Vasculopathy with Choroidal Vascular HyperpermeabilityAmerican Journal of Ophthalmology, 2006
- Polypoidal Choroidal Vasculopathy and Retinochoroidal Anastomosis in Japanese Patients Eligible for Photodynamic Therapy for Exudative Age-Related Macular DegenerationJapanese Journal of Ophthalmology, 2006